Reaction
Relapsing-Remitting Multiple Sclerosis reporting signals
As of the last recalculation, Relapsing-Remitting Multiple Sclerosis appears in 852 FAERS reports alongside 28 co-occurring drug terms. The strongest observed disproportionality signal is DOXEPIN HYDROCHLORIDE (PRR 184.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Doxepin Hydrochloride | 86 | 184.9 | 186.2 |
| Siponimod | 55 | 160.9 | 161.9 |
| Pramipexole | 62 | 106.5 | 106.9 |
| Rabeprazole | 86 | 105.3 | 105.7 |
| Rosuvastatin Calcium | 80 | 76.5 | 76.7 |
| Rabeprazole Sodium | 71 | 69.3 | 69.5 |
| Dalfampridine | 132 | 53.0 | 53.1 |
| Fingolimod Hcl | 141 | 47.5 | 47.6 |
| Baclofen | 137 | 46.1 | 46.2 |
| Dimethyl Fumarate | 175 | 43.5 | 43.5 |
| Cladribine | 16 | 41.4 | 41.5 |
| Ofatumumab | 49 | 38.2 | 38.2 |
| Thiamine Hydrochloride | 19 | 38.1 | 38.2 |
| Biotin | 39 | 32.0 | 32.0 |
| Interferon Beta-1A | 195 | 31.7 | 31.7 |
| Glatiramer Acetate | 69 | 30.6 | 30.6 |
| Ocrelizumab | 71 | 30.4 | 30.5 |
| Cyanocobalamin | 38 | 29.5 | 29.5 |
| Thiamine Hydrochloride, Riboflavin 5 Phosphate Sodium, Dexpanthenol And Niacinamide | 35 | 29.4 | 29.4 |
| Interferon Beta-1B | 21 | 27.4 | 27.4 |
| Alemtuzumab | 21 | 27.2 | 27.2 |
| Amantadine | 14 | 22.5 | 22.5 |
| Teriflunomide | 39 | 22.0 | 22.1 |
| Mesna Injection | 7 | 20.9 | 20.9 |
| Mesna | 7 | 20.5 | 20.5 |
| Natalizumab | 110 | 16.8 | 16.8 |
| Peginterferon Beta-1A | 8 | 15.0 | 15.1 |
| Diroximel Fumarate | 6 | 12.4 | 12.4 |